Cancer Prevention

癌症预防

• 批准号: 8557661
• 负责人: ROY A. JENSEN
• 金额: $ 2.37万
• 依托单位: UNIVERSITY OF KANSAS MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-11 至 2017-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8557661
• 关键词: Accounting; Adverse effects; Area; Aromatase Inhibitors; Award; Behavior Therapy; Biological Factors; Biological Markers; Biology; Biometry; Body Weight decreased; Breast; Breast Cancer Prevention; Cancer Burden; Cancer Center Support Grant; Cancer Control; Cancer Survivor; Cancerous; Cardiac; Curcumin; Development; Early Diagnosis; Funding; Future; General Population; Goals; Grant; Growth; Hormone replacement therapy; Human; Impaired cognition; Instruction; Intervention; Journals; Knock-out; Lead; Life; Malignant Neoplasms; Mammary Gland Parenchyma; Manuscripts; Modeling; Molecular; Molecular Abnormality; Molecular Target; Natural Product Drug; Noninfiltrating Intraductal Carcinoma; Omega-3 Fatty Acids; Organ; Ovarian; Peer Review; Phase; Play; Pre-Clinical Model; Premalignant; Prevention; Prevention program; Preventive Intervention; Primary Prevention; Process; Prostate; Publications; Quality of life; RNA-Binding Proteins; Rattus; Research; Research Personnel; Resource Sharing; Risk; Risk Reduction; Scientific Advances and Accomplishments; Secondary Cancer Prevention; Site; Testing; Time; Tissue Sample; Underserved Population; Woman; cancer prevention; control trial; energy balance; falls; flaxseed lignan; improved; in vivo; informatics shared resource; malignant breast neoplasm; member; mouse model; novel; population health; programs; research and development; response; survivorship; translational clinical trial; tumor progression

PROJECT SUMMARY (See instructions): The Cancer Prevention (CP) program is led by Carol J. Fabian, WID and has as its primary goal the discovery of processes and biomarker changes important early in cancer development, and the use of these biomarkers as response indicators in early-phase translational trials of new prevention interventions. An additional goal is to test interventions which may enhance quality of life in cancer survivors. CP theme areas are: 1) Precancerous Biology and Risk Biomarkers, 2) Prevention Translational Trials, and 3) Survivorship Research Membership: 18 Full and 9 Associate. CP members garnered over $6.2 million in total funding in 2010, of which $5.2 million was peer-reviewed and $1.8 million NCI funded. Between 2006 and 2010 CP members had 204 peer-reviewed manuscripts related to prevention or survivorship. The average Journal Impact Factor was 4.23 and average number of times a publication was cited was 14.07. Overall, CP members accounted for 35.7% of the usage ofthe Biospecimen Shared Resource, 26.83% ofthe usage ofthe Biostatistics & Informatics Shared Resource, and 0.41% ofthe usage ofthe Lead Development & Optimization Shared Resource in 2010. Value Added by the CP Program includes: 1) Multi-PI Awards: (Komen Multi-PI Promise Grant awarded in 2010 involving seven CP full members and two associate members) and 2) Translational Clinical Trial accrual from NCI funded projects. Total interventional trial accrual 2006-2010 was 477 with 136 subjects accrued to NCI-funded investigator-initiated Phase II primary prevention trials requiring breast tissue sampling. Key Scientific Accomplishments in Pre-Cancerous Biology and Risk Biomarkers include, development of an orthotopic mouse model for in vivo growth of human breast DCIS, development of a model of simultaneous breast and ovarian pre-cancer, and demonstration that RNA-binding proteins may play a key role in Gl tumor progression; in Prevention Translational Trials demonstration in pilots of favorable modulation of breast tissue risk biomarkers by a flaxseed lignan, and an aromatase inhibitor in women on hormone replacement therapy; in Survivorship Research the development of a successful weight loss programs for breast cancer survivors with modulation of risk biomarkers. These pilots were converted to peer-reviewed funded controlled trials. Future Directions in: 1) Pre-Cancerous Biology and Risk Biomarkers include characterization of precancerous molecular changes in several organs, development of novel pre-clinical models for prevention such as the p53 conditional knockout rat, and with investigators in D3ET, development of natural product derivatives which target identified molecular abnormalities; 2) Prevention Translational Trials along with CCPH and CB include flaxseed lignan, energy balance and omega-3 fatty acids for breast cancer prevention, curcumin for Barrett's, and energy balance and natural products for prostate; and 3) Survivorship research along with investigators in CCPH and D3ET will continue efforts in energy balance, and prevention of late cardiac and cognitive dysfunction side effects.

项目总结（见说明）： 癌症预防（CP）计划由WID的Carol J. Fabian领导，其主要目标是发现癌症发展早期重要的过程和生物标志物变化，并将这些生物标志物用作新预防干预措施早期转化试验的反应指标。另一个目标是测试可能提高癌症幸存者生活质量的干预措施。国家方案主题领域是：1）癌前生物学和风险生物标志物，2）预防转化试验，3）生存研究成员：18名正式成员和9名副成员。CP成员在2010年获得了超过620万美元的资金，其中520万美元是同行评审的，180万美元是NCI资助的。在2006年至2010年期间，CP成员有204篇与预防或生存有关的同行评审手稿。平均期刊影响因子为4.23，平均引用次数为14.07。总体而言，2010年，CP成员占生物标本共享资源使用量的35.7%，生物统计学和信息学共享资源使用量的26.83%，以及铅开发和优化共享资源使用量的0.41%。CP计划的增值包括：1）多PI奖：（2010年授予的科门多PI承诺奖，涉及7名CP正式成员和2名准成员）和2）NCI资助项目的转化临床试验应计费用。2006-2010年的干预性试验累积总数为477例，其中136例受试者累积至需要乳腺组织采样的由NCI-Functionator发起的II期一级预防试验。在癌前生物学和风险生物标志物方面的关键科学成就包括，开发了用于人乳腺DCIS体内生长的原位小鼠模型，开发了同时发生乳腺癌和卵巢癌前病变的模型，并证明了RNA结合蛋白可能在GI肿瘤进展中起关键作用;在预防转化试验中证明了亚麻籽木脂素对乳腺组织风险生物标志物的有利调节，和芳香化酶抑制剂在妇女激素替代治疗;在生存研究的发展成功的减肥计划乳腺癌幸存者与调制的风险生物标志物。这些试点被转换为同行评审资助的对照试验。未来方向：1）癌前生物学和风险生物标志物包括表征几个器官中的癌前分子变化，开发新的临床前生物标志物， 用于预防的模型，例如p53条件性敲除大鼠，以及与D3 ET的研究者一起，开发针对已鉴定的分子异常的天然产物衍生物; 2）与CCPH和CB一起的预防转化试验沿着包括亚麻籽木酚素、用于乳腺癌预防的能量平衡和ω-3脂肪酸、用于巴雷特氏病的姜黄素以及用于前列腺的能量平衡和天然产物;以及3）存活率 研究沿着CCPH和D3 ET的研究人员将继续努力实现能量平衡，并预防晚期心脏和认知功能障碍的副作用。